CClinicalTrials.gg
Status unknownNCT05169645STOP CSUAUpdated Dec 27, 2021

STOP CSUA: phySical acTivity, mOod and sleeP in Chronic Spontaneous Urticaria and Angioedema

An observational study in Chronic Spontaneous Urticaria, sponsored by St. James's Hospital, Ireland. Status unknown at 1 site in Ireland. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2021-12-27.

Sponsored by St. James's Hospital, Ireland · Observational

The sponsor has not verified this record recently (last verified Dec 2021), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
40
Ages
16 Years and older
Sex
All
01

Study summary

Chronic spontaneous urticaria and angioedema (CSUA) is a disease of the skin characterised by hives, swellings or both that last longer than 6 weeks. People with this disease commonly describe poor sleep, reduced quality of life and psychological difficulties such as depression and anxiety. This study seeks to understand relationships between physical activity, sleep and symptoms of urticaria. We are asking individuals with urticaria to wear a fitbit tracker which monitors their physical activity and sleep. Participants also download an app onto their smartphone called Athena CX which is designed by the study team in DCU. The purpose of the app is capture real-time information from participants on mood and any skin symptoms they experience. We will use this information to learn more about possible links between symptoms of urticaria and lifestyle behaviours.

Read the detailed description

Chronic spontaneous urticaria and angioedema (CSUA) is a disease of the skin characterised by hives, swellings or both that last longer than 6 weeks (1). A quarter of patients with this disease report impaired quality of life (2). Furthermore, individuals with CSUA are more likely to have depression and anxiety (3). In addition, our previous qualitative research findings have noted issues with self-compassion among this cohort (4). Fatigue and poor sleep are common (5). We seek to examine possible links between physical activity, sleep, mood and symptoms of urticaria.

For participants who give their consent, we will do this by collecting and exploring:

  • Fitbit tracker data
  • Information on mood via the Athena CX app
  • Information on symptoms of urticaria via the Athena CX app

Electronic health applications for smartphones are increasingly used in chronic health conditions and have been piloted in chronic spontaneous urticaria for recording of symptoms, medication reminders and patient education. This study will develop a smartphone application designed specifically for this cohort of patients, entitled Athena CX focusing specifically upon symptomatology and mood.

An observational study collecting biofeedback data in this cohort will inform our understanding of this disease and future research.

Objectives

  1. To delineate the psychological symptoms encountered by this cohort of patients
  2. To examine whether there is a link between biofeedback data and symptoms of chronic spontaneous urticaria and angioedema (CSUA)
  3. To collect linked clinical data on participants with CSUA
  4. To inform an RCT examining the use of a digital behavioural intervention for patients with CSUA
02

Conditions studied

  • Chronic Spontaneous Urticaria
03

In context

Urticaria

237 studies on the registry are indexed under Urticaria; 26 are open to participants now.

This study's planned enrollment of 40 is below the median of 162 across 52 observational studies indexed under Urticaria.

Browse Urticaria studies →

Lead sponsor

St. James's Hospital, Ireland is the lead sponsor of 28 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Chronic spontaneous urticaria clinic

Inclusion criteria

  1. Clinical diagnosis of chronic spontaneous urticaria with or without angioedema
  2. Urticaria control test score \< 12 indicating poorly controlled urticaria at time of consent
  3. Preference to participate in the study
  4. In possession of a smartphone

Exclusion criteria

Exclusion Criteria:

Unable or unwilling to provide informed consent

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
40 participants (estimated)
Patient registry
No

Groups and cohorts

  • CSUA patients

    CSUA patients

    Other: Physical activity monitoring - Symptom monitoring

Interventions

  • OtherPhysical activity monitoring - Symptom monitoring

    This is an observational study. There is no intervention outside the collection of data from participants. Consenting participants in the study will be provided with a Fitbit activity tracker and asked to wear it for a period of three months. The Fitbit measures: * Physical activity using daily step count * Additional physical activity entries * Heart rate * Sleep quality * Calories burned * Food log Participants will be asked to download an app onto their smart phone entitled Athena CX. This app is designed to capture: * Urticaria symptomatology using the urticaria control test * Symptoms of depression using 2 items from the PHQ 9 * Symptoms of anxiety using two items from the GAD * Short form self-compassion scale

06

What researchers measure

Primary outcomes

  1. Physical activity

    Step count as measured by fitbit

    Time frame: Followed for 12 weeks during programme

  2. Urticaria symptomatology

    Urticaria control test score

    Time frame: Followed for 12 weeks during programme

  3. Heart rate variability

    Heart rate variability

    Time frame: Followed for 12 weeks during programme

07

Study locations

1 site
  • St. James's Hospital
    Dublin, Ireland
    • Katie Ridge · Contact
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 27, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05169645
Lead sponsor
St. James's Hospital, Ireland
Responsible party
Dr. Katie Ridge (Immunology specialist registrar, St. James's Hospital, Ireland) — Principal investigator
First posted
Dec 27, 2021
Start date
Feb 1, 2022 (estimated)
Primary completion
Sep 1, 2022 (estimated)
Completion
Feb 1, 2023 (estimated)
Last update
Dec 27, 2021

Study contacts

Katie Ridge
Contact
kridge@stjames.ie
014162928
Niall Conlon
principal investigator · St. James's Hospital, Ireland

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion